WaveMan · Form 4
Epperly Melissa B, insider trades
> Search tickers & screens ⌘K
LIVE

Epperly Melissa B, insider trades

Epperly Melissa B, has filed 44 Form 4s with the SEC that we hold, for Roivant Sciences Ltd. (ROIV) (Director), Zentalis Pharmaceuticals, Inc. (ZNTL) (Chief Financial Officer), Nautilus Biotechnology, Inc. (NAUT) (Director) and KNTE (Director). Across all of them we count 2 purchases worth $499.8K and 24 sales worth $4.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 7 sales ($2.6M). The largest single trade was a sale of 41,861 shares of Roivant Sciences Ltd. worth $1.2M, dated 2026-03-16. Of 4 sales filed since we began reading the 10b5-1 checkbox, 4 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-07-06 and the latest 2026-10-05.

Roivant Sciences Ltd. (ROIV)

Director · 24 filings · 7 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-03-16S, sale reported on Form 441,861$1.2M2026-03-18
2026-06-29S, sale reported on Form 415,002$514.9K2026-07-01
2026-06-29S, sale reported on Form 42,748$95.4K2026-07-01
2026-09-15S, sale reported on Form 44,338$172.0K2026-09-17
2026-09-15S, sale reported on Form 4600$24.2K2026-09-17
2026-10-01S, sale reported on Form 416,850$607.9K2026-10-05
2026-10-01S, sale reported on Form 4900$32.9K2026-10-05

Zentalis Pharmaceuticals, Inc. (ZNTL)

Chief Financial Officer · 12 filings · 19 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-01S, sale reported on Form 4700$35.1K2021-07-06
2021-07-01S, sale reported on Form 41,378$70.5K2021-07-06
2021-07-01S, sale reported on Form 4200$10.6K2021-07-06
2021-07-01S, sale reported on Form 4805$41.9K2021-07-06
2021-08-18P, purchase reported on Form 41,326$69.0K2021-08-20
2021-08-19P, purchase reported on Form 48,285$430.8K2021-08-20
2022-02-23S, sale reported on Form 41,211$59.1K2022-02-23
2022-02-23S, sale reported on Form 4702$34.8K2022-02-23
2022-04-04S, sale reported on Form 4353$18.5K2022-04-05
2022-04-04S, sale reported on Form 44,512$234.6K2022-04-05
2022-04-04S, sale reported on Form 42,818$142.9K2022-04-05
2022-04-04S, sale reported on Form 41,303$65.0K2022-04-05
2022-04-04S, sale reported on Form 48,094$394.6K2022-04-05
2023-02-13S, sale reported on Form 42,624$53.6K2023-02-14
2023-02-14S, sale reported on Form 45,227$104.4K2023-02-14
2023-10-04S, sale reported on Form 4888$17.7K2023-10-06
2023-10-04S, sale reported on Form 44,594$89.3K2023-10-06
2024-02-02S, sale reported on Form 48,669$100.0K2024-02-05
2024-02-12S, sale reported on Form 42,573$29.4K2024-02-12

Nautilus Biotechnology, Inc. (NAUT)

Director · 5 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

KNTE

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1807359) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms